In the 1990s, exendin-4, a GLP-1 receptor agonist (GLP-1 RA) structurally similar to endogenous GLP-1, was isolated from Gila monster venom, which subsequently led to the approval of exenatide for type 2 diabetes mellitus (T2DM) management in 2005 [2]
e CV, cardiovascular
Use of these drugs has surged: from 2019 to 2024 in the US, prescriptions for patients with obesity without diabetes rose by nearly 2,000%
Diabetes Res Clin Pract 183:109080 Sato T, Shimizu T, Fujita H, Imai Y, Drucker DJ, Seino Y et al (2020) GLP-1 receptor signaling differentially modifies the outcomes of sterile vs viral pulmonary inflammation in male mice
Wipe the neck with an alcohol swab in a circular motion
Sprout is focused solely on GLP-1 weight loss medications and aims to make the process hassle-free